Amneal Pharmaceuticals (AMRX) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

$0.30

Estimate

$0.23

Surprise

+30.3%

Score at report (before → after)

5.4 → 5.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Amneal Pharmaceuticals (AMRX) beat the $0.23 estimate with adjusted EPS of $0.30 — a large 30.3% upside surprise. TrendMatrix's engine moved from Hold (5.4/10) to Sell at 5.5/10 after the report.

TrendMatrix currently rates AMRX Sell at 5.7/10.

3 of the last 4 quarters beat the estimate; this quarter's +30.3% surprise compares with a +34.7% four-quarter average. Next scheduled report: 2026-10-29.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$19.51

Price target

$19.76

Stop

$18.14

Upside to target

+1.3%

Reward-to-risk

0.1:1

Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$6.73B

P/E (fwd)

16.2

P/E (ttm)

40.3

52-week range

$9.49–$21.18

Off 52-week high

7.9%

RSI (14)

62

Volume vs avg

0.02×

Score today

5.7/10